Avacta Share Discussion Threads

[boxer_1] 12/8/2021 08:24

Everybody wishes they have sold at £2.80 !!!

[tickboo] 12/8/2021 08:22

I agree that SNG could be massive.

[boxer_1] 12/8/2021 08:21

THICKBOO UR TOO THICK AND U GNA REMAIN THICK JUST LIKE OTHER IDIOTS OVENMAN, BOYSIE

[tickboo] 12/8/2021 08:15

Antigen LFTs selling fast but antibody a waste of time.

[money4me] 12/8/2021 08:12

Sold a pup

[pwhite73] 12/8/2021 08:12

From the ABDX RNS 12/08/2021 - "The Company has not seen significant commercial traction with the AbC-19(TM) product to date"

Sadly this applies to all UK LFT manufacturers. As I posted earlier the only clients are governments. If a company is not selling to a government then it has no sales.

[david gruen] 12/8/2021 08:09

Finally!

Not far to go now guys. 90-100p.

[amanitaangelicus] 12/8/2021 08:08

Tickb ... it.s Avacta paid for research ... a marketing/promotional spend unfortunately and the general mkt wont be interested in it in the slightest. I.d love to see way more non paid for coverage/research outlook stuff but this wont happen until the latest C trials progress. Mkt sentiment is/has moved against all things covid testing related. Synairgen remains my only big hope now. Holding here reduced this morning. Lost 5k ish. Not a deramp, just reality given the lack of volume /interest in the share at the moment. Nova/Abingdon/ Odx taken as a bunch, worries me. I.m currently looking at gene therapy businesses. GLA.

[tickboo] 12/8/2021 08:06

Trinity Delta view: The start of the Phase I study of lead therapeutic asset AVA6000 marks Avacta's transition to a clinical stage company. AVA6000 is the first programme from its two proprietary platforms, Affimer and pre|CISION, to enter human trials. The Phase I trial will be important in establishing clinical proof of concept; if it demonstrates that AVA6000 is effective in reducing the systemic toxicity of doxorubicin, this would validate the pre|CISION pro-drug concept and this approach for multiple related programmes. This would open up a broader pipeline of proprietary opportunities for Avacta and potentially also increase industry interest in the pre|CISION platform. Avacta is working on several other pre|CISION pro-drugs whose clinical utility would benefit from improved efficacy and reduced toxicities. The most advanced of which is FAP-activated proteasome inhibitor, AVA3996, a prodrug of an analogue of Takeda's Velcade (bortezomib). We currently value Avacta at £710m, or 280p per share, with the Diagnostic opportunities representing £133m and the Therapeutic pipeline rNPV £559m.

[boxer_1] 12/8/2021 08:04

None of these companies sold a single fkn test in the last 20 months or so …..

[boxer_1] 12/8/2021 08:03

Going back to a penny share and rightly so for a company badly run that has sold nothing but options!!!!!!!!

[boxer_1] 12/8/2021 08:03

Going back to a penny share and rightly so for a company badly run that has sold nothing but options!!!!!!!!

[tickboo] 12/8/2021 07:48

https://www.trinitydelta.org/wp-content/uploads/2021/08/AVCT-Lighthouse-210811.pdf

[roberts1975] 12/8/2021 07:39

Looking for 109p

[amanitaangelicus] 12/8/2021 07:37

Cheshire Pete - fair enough. Abingdon is in the mire. Nova are going nowhere. ODX slipping. Tricky days. Gov seems 'happy' with the current death rate, hosp nos, infections and the economy reopening. Was on Cambridge Science Park yesterday - so much high tech stuff going, fledgling tech/bio p companies. Everywhere down here makes the NE look like a second rate, 2 bit forgotten region. As for pub meal prices - fk me! And that.s for a main course the size of a hamster. GLA ps I.m getting nervy.

[viking24] 12/8/2021 07:22

Abingdon numbers out, not being paid, stock down 20%They were removed by FDA as well

[cheshire pete] 12/8/2021 07:22

onsideman: Think the COVID story drove the share price to 275p. The market has discounted the LFT never going to happen imo and the share price is now close to the placing value, which would have been set at a level institutional investors were happy with.

[amanitaangelicus] 12/8/2021 07:07

Volsung ...youmre correct. Onesideman - you.re correct too - take out expected LFT revenues and this would be valued at say 100m ... due to cash in bank and some IP on the balance sheet. C stuff is now 'go' trialwise.A big payments/ royalty stuff by the S Koreans for anything they.ve got going Affimer based researchwise would be gold dust. At the mo the share price is largely a function of expected LFT sales, cash in the bank and IP value. Sorry but that.s it - that.s the game at the mo. Hold.GLA

[david gruen] 12/8/2021 07:04

Open blue (when PIs make their trading decisions.), drop it throughout the day. Close on the low (when the pros make their trading decisions).

90-100p target remains.